BioSpace News Archive

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with two new Phase 2 studies.

- Katherine Vega Stultz appointed as chief operating officer - Philip P. Gutry appointed as chief business officer and head of finance & investor relations - Executive hires follow appointment of Dr. Josh Lehrer as chief executive officer

BrainTale, a French innovative company dedicated to enabling adapted care for brain injured patients in clinical routine with its portfolio of quantification and prediction digital medical devices in neurology and intensive care, announced the completion of its first financing round securing more than 1M€ of funding.

NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today the launch of a mobile phlebotomy service for its blood-based tests, including InVisionFirst Lung, its advanced non-small cell lung cancer liquid biopsy test,

Customized cell analyzer installed in Naples, Italy for biomedical research and water monitoring

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new data from two ongoing clinical trials evaluating CMP-001, Checkmate’s Toll-like receptor 9 (TLR9) agonist,

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020.

Castellum, Inc. (OTC: ONOV) announces filing its third quarter (Q3) operating results for the period ended September 30, 2020

Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells

Dynatronics Corporation, a leading manufacturer of athletic training, physical therapy, and rehabilitation products, announced the appointment of Norman Roegner III as Chief Financial Officer, effective November 9, 2020.